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Summary
In the bone marrow, the special microenvironment
niches nurture a pool of hematopoietic stem cells
(HSCs). Many HSCs reside near the vasculature, but
the molecular regulatory mechanism of niches for
HSC maintenance remains unclear. Here we showed
that the induced deletion of CXCR4, a receptor for
CXC chemokine ligand (CXCL) 12 in adult mice, re-
sulted in severe reduction of HSC numbers and in-
creased sensitivity to myelotoxic injury, although it
did not impair expansion of the more mature progeni-
tors. Most HSCs were found in contact with the cells
expressing high amounts of CXCL12, which we have
called CXCL12-abundant reticular (CAR) cells. CAR
cells surrounded sinusoidal endothelial cells or were
locatednear theendosteum.CXCL12-CXCR4signaling
plays an essential role in maintaining the quiescent
HSCpool, andCARcells appear to be a key component
of HSC niches, including both vascular and endosteal
niches in adult bone marrow.
Introduction
Hematopoietic stem cells (HSCs) give rise to all types of
blood cells including lymphocytes and myeloid cells. In
the bone marrow, the niches where HSCs reside are
thought to supply the requisite factors and play an
essential role in maintaining a pool of HSCs to provide
the appropriate numbers of mature blood cells through-
out life (Moore and Lemischka, 2006; Wilson and
Trumpp, 2006). Most primitive hematopoietic cells, in-
cluding HSCs, are thought to be in a quiescent G0 state
in these niches, probably to prevent depletion of the
regenerative cell pool or sensitivity to myelotoxic injury
(Cheshier et al., 1999). Therefore, it is important to un-
derstand the molecular regulatory mechanism of niches
for maintenance of the stem cell pool, not only for stem
cell and developmental biology of lymphohematopoietic
cells but also for bone marrow transplantation and gene
therapy requiring HSCs. It was reported previously that
osteoblasts lining the bone surface act as HSC niches
(Calvi et al., 2003; Zhang et al., 2003) and that Angiopoie-
tin-1 (Ang-1), observed exclusively in osteoblasts, main-
tains HSC quiescence (Arai et al., 2004). In contrast,
imaging of HSCs reveal that many HSCs are associated
*Correspondence: tnagasa@frontier.kyoto-u.ac.jpwith sinusoidal endothelium although only some HSCs
adjoin the endosteum (Kiel et al., 2005). Nevertheless,
the precise cellular components and niche-derived
factors regulating HSCs in the vascular niches remain
unclear.
CXC chemokine ligand (CXCL)12 (also known as stro-
mal cell-derived factor [SDF]-1 or pre-B-cell-growth-
stimulating factor [PBSF]) is a member of a large family
of structurally related chemoattractive cytokines and
was first characterized as a growth-stimulating factor
for the B cell precursor clone (Nagasawa et al., 1994).
The primary physiologic receptor for CXCL12 is
CXCR4, a hepta helical receptor coupled to heterotri-
meric guanosine triphosphate (GTP) binding proteins,
which also functions as an entry receptor for the HIV-1
virus (Nagasawa et al., 1996; Tachibana et al., 1998;
Zou et al., 1998). Studies of mutant mice with targeted
gene disruption have revealed that CXCL12-CXCR4
signaling is essential for hematopoiesis, including B cell
development and colonization of bone marrow by hema-
topoietic progenitors, including HSCs, during ontogeny
as well as cardiovascular formation and neurogenesis
(Ara et al., 2003; Nagasawa et al., 1996; Nagasawa,
2006; Tachibana et al., 1998; Zou et al., 1998). Lethality
caused by deficiencies of CXCL12 and CXCR4 prevents
immediate analysis of their role in adult hematopoiesis.
Treatment with CXCR4-selective antagonist induces
increase in HSCs in the peripheral blood, suggesting
a role for CXCL12 in retaining HSCs in hematopoietic
organs (Broxmeyer et al., 2005). In addition, treatment
of immature human bone marrow CD34+ cells with
CXCR4 antibodies prevents the engraftment of primitive
human nonobese diabetic-severe combined immunode-
ficiency (NOD-SCID) mouse repopulating cells (SRCs)
(Peled et al., 1999). However, experiments with radiation
chimeras have revealed only a modest reduction in long-
term myeloid reconstitution by Cxcr42/2 fetal liver cells
(Kawabata et al., 1999; Ma et al., 1999). Therefore, the
roles of CXCL12-CXCR4 signaling in HSCs within adult
bone marrow remain unclear.
Here we show that CXCL12-CXCR4 signaling is es-
sential in adult bone marrow to maintain the HSC pool
and suggest that many HSCs are in contact with a small
population of reticular cells expressing high amounts of
CXCL12 (Tokoyoda et al., 2004). In addition, almost all
HSCs near the sinusoidal endothelium appear to be in
contact with these reticular cells surrounding endothe-
lial cells in the extravascular spaces, suggesting that
these cells are the key cellular components of HSC vas-
cular niches.
Results
Induced Deletion of CXCR4 in Adult Bone Marrow
To determine the roles of CXCL12-CXCR4 signaling in
hematopoiesis in adult animals, we generated CXCR4
conditionally deficient mice. We crossed mice with a
loxP-CXCR4 conditional targeting allele (CXCR4flox(f)/null
mice) (Tokoyoda et al., 2004) to MxCre mice (Kuhn
et al., 1995) in which Cre was expressed after the
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978Figure 1. Hematopoiesis in Adult Bone Mar-
row from CXCR4 Conditionally Deficient Mice
(A) QRT-PCR analysis of mRNA expression of
CXCR4 in c-kit+Sca-1+Lin2 cells in the bone
marrow from pIpC-treated MxCre-CXCR4f/null
(f/null) and MxCre-CXCR4f/wt (f/wt) mice at 16
weeks after the final pIpC treatment (n = 3,
p = 0.009).
(B) Flow cytometric analysis of the numbers
of B220+IgM2 B cell precursors, B220+IgM+
B cells, Gr-1+ myeloid lineage cells and
Ter119+CD71+ erythroblasts in bone marrow
from pIpC-treated MxCre-CXCR4f/null and
MxCre-CXCR4f/wt mice at 16 weeks after final
pIpC treatment (n = 3; *p < 0.02; **p < 0.05).
Error bars represent SD of the mean.induction of interferon by the administration of poly(I)-
poly(C) (pIpC) to inactivate the CXCR4 gene in the adult
animals. The floxed allele was excised almost com-
pletely in bone marrow c-kit+Sca-1+Lineage (Lin)2 prim-
itive hematopoietic cells and myeloid lineage cells of
some pIpC-treated MxCre-CXCR4f/null mice as analyzed
by quantitative, real-time polymerase chain reaction
with reverse transcription (qRT-PCR) and flow cytome-
try (Figure 1A and data not shown). Flow cytometric
analysis revealed that the bone marrow of pIpC-treated
MxCre-CXCR4f/null mice contained severely reduced
numbers of B cells but modestly reduced numbers of
myeloid or erythroid lineage cells compared with control
MxCre-CXCR4wt/wt or MxCre-CXCR4f/wt mice (Fig-
ure 1B). In peripheral blood, most pIpC-treated MxCre-
CXCR4f/null mice showed increased myeloid lineage
cells (data not shown). These results are consistent
with the known phenotype of mice reconstituted with
CXCR4-deficient fetal liver cells (Kawabata et al., 1999;
Ma et al., 1999).
HSCs Are Severely Reduced in Adult Bone Marrow
of CXCR4 Conditionally Deficient Mice
HSCs can be highly purified as CD342c-kit+Sca-1+Lin2
cells (Osawa et al., 1996). In addition, stem cells have the
differential ability to efflux Hoechst dye, which defines
a small subset of side population (SP) cells (Goodell
et al., 1996, 1997). SP cells with higher amounts of
Hoechst efflux (lower SP) are a nearly homogeneous
subset of bone marrow HSCs (Camargo et al., 2006),
and they can reconstitute myeloablated mice with abso-
lute efficiency (Matsuzaki et al., 2004). Consistent with
these, the numbers of CD342c-kit+Sca-1+Lin2 cells
were similar to those of lower SP (SPlow) cells and in-
creased with age in wild-type bone marrow (data not
shown; Sudo et al., 2000).
pIpC reversibly inhibited expansion of primitive hema-
topoietic cells, probably reflecting a transient antiproli-
ferative and/or apoptotic effect of interferon induced
by pIpC treatment (Gidali et al., 1981). In addition, the
numbers of CD342c-kit+Sca-1+Lin2 and SPlow cells
were reduced in pIpC-treated wild-type and control
MxCre-CXCR4f/wt mice as well as MxCre-CXCR4f/null
mice at early time points after injection of pIpC (see
Figure S1 in the Supplemental Data available online
and data not shown). Therefore, we analyzed the role of
CXCR4 in HSCs via pIpC-treated MxCre-CXCR4f/null
and control mice at the late stages after pIpC injectionwhen the mice recovered from the effects of pIpC in
terms of the HSC numbers. Multiparameter flow cyto-
metric analysis revealed that the numbers of CD342
c-kit+Sca-1+Lin2 and SPlow cells in bone marrow were
comparable in pIpC-treated MxCre-CXCR4f/wt mice but
severely reduced in pIpC-treated MxCre-CXCR4f/null
mice compared with pIpC-treated MxCre-CXCR4wt/wt
mice and untreated animals at 16 to 36 weeks after the
final pIpC injection (Figures 2A and 2B, and data not
shown), indicating that CXCL12-CXCR4 signaling is
required to maintain the HSC pool within bone marrow.
Next we compared the expression of genes that were
highly expressed in HSCs in the bone marrow c-kit+
Sca-1+Lin2 cell population in pIpC-treated MxCre-
CXCR4f/null and control mice. Among the genes involved
in HSC regulation, the expressions of Tek (encoding
Tie2), which is a physiologic receptor for Ang-1 (Arai
et al., 2004), Vegfa (Gerber et al., 2002), and Junb
(Passegue et al., 2004) increased in CD342c-kit+Sca-1+
Lin2 HSCs compared with CD34+c-kit+Sca-1+Lin2 cells,
which were enriched for non-self-renewing primitive
hematopoietic progeniters including multipotent pro-
genitors (MPPs) (Nakauchi et al., 1999; Osawa et al.,
1996) in wild-type mice via qRT-PCR (Figure 2C, left).
Gene expression analysis revealed that the expressions
of Tek, Vegfa, and Junb were markedly reduced in pIpC-
treated MxCre-CXCR4f/null mice compared with control
MxCre-CXCR4wt/wt orMxCre-CXCR4f/wt mice (Figure2C,
right; and data not shown). These results support the
idea that the reduction of CD342c-kit+Sca-1+Lin2 cell
numbers in pIpC-treated MxCre-CXCR4f/null mice re-
flected the decreased numbers of HSCs, but not merely
as a consequence of upregulated CD34 expression in
HSCs based on the amount of cell activation (Sato
et al., 1999) in these mutants.
The Numbers of LTC-ICs and CRUs in Adult Bone
Marrow of CXCR4 Conditionally Deficient Mice
We performed long-term in vitro cultures (LTCs) on pri-
mary bone marrow stromal cells via limiting dilution
LTC-initiating cell (IC) assays (Ploemacher et al., 1989;
Stier et al., 2005). The frequency of LTC-ICs has been
shown to correlate with in vivo repopulating potential
(Ploemacher et al., 1989). A marked reduction of LTC-
ICs was observed in bone marrow from pIpC-treated
MxCre-CXCR4f/null mice compared with control animals
(Figure 2D). This suggests that the numbers of HSCs
were reduced in CXCR4 conditionally deficient mice
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979Figure 2. Reduced HSC Pool in Adult Bone
Marrow in the Absence of CXCR4
(A and B) Flow cytometric analysis of HSCs
in bone marrow from pIpC-treated MxCre-
CXCR4f/null and MxCre-CXCR4f/wt mice.
(A) The frequencies (left) and the absolute
numbers (right) of CD342c-kit+Sca-1+Lin2
cells in the bone marrow (left, n = 6, p = 0.026;
right, n = 6, p = 0.031).
(B) Fluorescence staining profile of Lin2 SP
cells, where the boxed region is the lower SP
(SPlow) region (left and middle). The numbers
of SPlow cells in bone marrow (right; n = 6,
p = 0.0061).
(C) QRT-PCR analysis of mRNA expression of
Tek, Vegfa, and Junb in CD342c-kit+Sca-1+
Lin2 HSCs and CD34+c-kit+Sca-1+Lin2
HPCs in bone marrow from wild-type mice
(left, n = 3). QRT-PCR analysis of mRNA
expression of Tek, Vegfa, and Junb in
c-kit+Sca-1+Lin2 cells in bone marrow from
pIpC-treated MxCre-CXCR4f/null and MxCre-
CXCR4f/wt mice (right, n = 4).
(D) The numbers of LTC-ICs in bone marrow
from pIpC-treated MxCre-CXCR4f/null and
MxCre-CXCR4f/wt mice (n = 4, p = 0.019).
LTC-IC numbers per femur and tibia were
assayed by limiting dilution analysis.
(E) The numbers of CRU in the bone marrow
from pIpC-treated MxCre-CXCR4f/null and
MxCre-CXCR4f/wt mice (n = 2). Long-term
in vivo competitive repopulating unit (CRU)
numbers per femurs and tibias were assayed
by limiting dilution analysis.
(F) Flow cytometric analysis of HPCs in
bone marrow from pIpC-treated MxCre-
CXCR4f/null andMxCre-CXCR4f/wt mice.Thefre-
quencies (left) and the absolute numbers (right)
of CD34+c-kit+Sca-1+Lin2 hematopoietic pro-
genitor cells (HPCs) in the bone marrow (n = 4).
(G) QRT-PCR analysis of mRNA amounts of
CXCR4 in CD342c-kit+Sca-1+Lin2 HSCs and
CD34+c-kit+Sca-1+Lin2 HPCs in bone
marrow from wild-type mice (n = 4, p = 0.020).
Error bars represent SD of the mean.because in vitro studies showed that colony formation
per se in LTCs was unaffected by the administration of
CXCR4 selective antagonist (data not shown).
To further define the roles of CXCR4 in HSCs, the
limiting-dilution analysis was performed with long-term
in vivo competitive repopulating unit (CRU) assay to
detect and measure the frequency of the cells capable
of long-term lympho-myeloid repopulation in bone mar-
row cells (Szilvassy et al., 1990). Repopulation of the
hematopoietic system was analyzed for the presence
of myeloid cells in peripheral blood because they were
not obviously reduced in the absence of CXCR4 as men-
tioned above (Figure S2). The numbers of CRU in the
bone marrow of pIpC-treated MxCre-CXCR4f/null mice
was severely reduced compared with control animals
(Figure 2E).
Development of More Mature Hematopoietic
Progenitors in CXCR4 Conditionally Deficient Mice
In contrast to HSC reduction, CD34+c-kit+Sca-1+Lin2
progenitors were slightly increased in bone marrow
from most pIpC-treated MxCre-CXCR4f/null mice com-
pared with control pIpC-treated MxCre-CXCR4wt/wt or
MxCre-CXCR4f/wt mice by flow cytometric analysis(Figure 2F), suggesting that CXCL12 plays a specific
role in HSCs within primitive hematopoietic cells. Con-
sistent with this, qRT-PCR analysis revealed that
CXCR4 mRNA expression in CD342c-kit+Sca-1+Lin2
HSCs was higher than in CD34+c-kit+Sca-1+Lin2progen-
itors (Figure 2G).
Flow cytometric analysis of peripheral blood and
spleen revealed that CD342c-kit+Sca-1+Lin2 cells
were not observed in pIpC-treated MxCre-CXCR4f/null
and control mice, although the numbers of c-kit+
Sca-1lo/2Lin2 cells were increased in the mutants (Fig-
ure S3). These results suggest that CD342c-kit+
Sca-1+Lin2 cell reduction in bone marrow is not due to
defective retention in the marrow cavity. In addition, it
may be that CXCR4 is involved in the retention of
more mature c-kit+Sca-1lo/2Lin2 cells in bone marrow
and/or peripheral blood. Alternatively, extramedullary
hematopoiesis possibly occurs when HSCs in bone
marrow are severely reduced in the absence of CXCR4.
Susceptibility of CXCR4 Conditionally Deficient Mice
to Myelosuppressive Stress
The finding that CXCL12-CXCR4 signaling is essential
for maintaining the HSC pool led us to examine
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to myelosuppressive stress. Treatment of mice with an-
timetabolite 5-fluorouracil (5-FU) is selectively cytotoxic
for cycling hematopoietic cells, induces bone marrow
hypoplasia, and can cause lethality. However, quiescent
HSCs are thought to be resistant to the effect of 5-FU
and play a role in restoring hematopoiesis. When ani-
mals were treated weekly with 5-FU at a dose of 120
mg/kg, the survival frequency of pIpC-treated MxCre-
CXCR4f/null mice was much lower than that in control
MxCre-CXCR4f/wt mice (Figure 3). Thus, CXCR4-defi-
cient mice are vulnerable to myelosuppressive stress,
consistent with dramatic reduction of the HSC pool.
Enhanced Exit from Quiescent G0 Phase in the
Primitive Hematopoietic Progenitors of CXCR4
Conditionally Deficient Mice
Because CD34+c-kit+Sca-1+Lin2 cells in the bone mar-
row were slightly increased in most pIpC-treated
MxCre-CXCR4f/null mice, the cell-cycling status of prim-
itive hematopoietic cells was determined with the RNA-
specific dye pyronin Y (PY) in conjunction with DNA-spe-
cific dye Hoechst 33342 or proliferation marker Ki67 in
conjunction with the DNA-specific dye 7AAD as a mea-
sure of quiescence (Gerdes et al., 1984; Ladd et al.,
1997). Quiescent cells in G0 have a low RNA content
(low PY uptake) (Ladd et al., 1997), and Ki67 is expressed
in all actively dividing cells but not in quiescent (G0) cells
(Gerdes et al., 1984). Although most c-kit+Sca-1+Lin2
cells in control mice were quiescent in G0, the remain-
ing c-kit+Sca-1+Lin2 cells in pIpC-treated MxCre-
CXCR4f/null mice demonstrated a smaller fraction of low
PY uptake or Ki67-negative G0 cells and a larger fraction
of high PY uptake or Ki67-positive actively dividing
(G1+S+G2/M) cells, respectively (Figures 4A–4C). Be-
cause HSCs were severely decreased in the c-kit+Sca-
1+Lin2 cell population in the absence of CXCR4, these
results raised the possibility that exit from the quiescent
G0 phase was promoted in the remaining CD34
+
c-kit+Sca-1+Lin2 progenitors in CXCR4 conditionally
deficient mice. To address this possibility, we analyzed
the frequencies of cycling cells within the CD34+
Figure 3. Reduced Survival Frequency after 5-FU Treatment in the
Absence of CXCR4
5-FU was administered weekly, and survival data were analyzed by
a log-rank nonparametric test and expressed as Kaplan-Meier
survival curves (n = 9, p = 0.037). Unbroken black lines, pIpC-treated
MxCre-CXCR4f/wt mice; broken black lines, pIpC-treated MxCre-
CXCR4f/null mice.c-kit+Sca-1+ compartment. CD34+c-kit+Sca-1+ cells in
pIpC-treated MxCre-CXCR4f/null mice comprised a
smaller fraction of Ki67-negative G0 cells and a larger
fraction of Ki67-positive actively dividing (G1+S+G2/M)
cells, compared with CD34+c-kit+Sca-1+ cells in control
Figure 4. Increased Fraction of the Primitive Hematopoietic Progen-
itors in Active Cell Cycle in the Bone Marrow from CXCR4 Condition-
ally Deficient Mice
Flow cytometric analysis of the bone marrow from pIpC-treated
MxCre-CXCR4f/null and MxCre-CXCR4f/wt mice.
(A) Fluorescence staining profile of c-kit+Sca-1+Lin2 cells after stain-
ing with PY and Hoechst 33342.
(B) Fluorescence staining profile of c-kit+Sca-1+ cells after staining
with Ki67 and 7AAD.
(C) The percentage of G0 cells (Ki67-negative) in G0/G1 fraction (left)
and the percentage of G1+S+G2/M cells (Ki67-positive, right) in
c-kit+Sca-1+ cell population (left, n = 3, p = 0.008; right, n = 3, p =
0.007). Error bars represent SD of the mean.
(D) The percentage of G0 cells (Ki67-negative) in G0/G1 fraction (left)
and the percentage of G1+S+G2/M cells (Ki67-positive, right) in
CD34+c-kit+Sca-1+ cell population (left, n = 3, p = 0.045; right,
n = 3, p = 0.043). Error bars represent SD of the mean.
Maintenance of the HSC Pool by CXCL12 in BM Niches
981chimeras (Figure 4D). This indicated that increased
percentages of G1+S+G2/M cells in c-kit
+Sca-1+ cells
were partly due to the promotion of mitotic cycling in
the remaining CD34+c-kit+Sca-1+ progenitors but not
merely the reduction of G0 HSC numbers in the mutants.
Cell-Intrinsic Alterations in HSCs and an Altered
Microenvironment in the Absence of CXCR4
To examine the consequence of CXCR4 deficiency on
hematopoietic cells and the contribution from a mutant
microenvironment, we generated mice with mixed chi-
meric bone marrow cells in which conditionally targeted
cells could be distinguished from wild-type competitors
by surface marker expression. Bone marrow cells derived
from MxCre-CXCR4f/null or MxCre-CXCR4f/wt mice carry-
ing the Ly5.2+Ly5.12 alleles were mixed with wild-type
Ly5.22Ly5.1+ competitor marrow cells and transferred
into lethally irradiated Ly5.22Ly5.1+ mice. Analysis of
the surface expression of Ly5.1 by flow cytometry re-
vealed that donor-derived MxCre-CXCR4f/null or MxCre-
CXCR4f/wt cells contributed comparably to peripheral
blood cells in these recipient mice 12 weeks after
transfer. They maintained approximately 80% Ly5.2+
Ly5.12 peripheral blood cells. Mice were then treated
with pIpC to induce excision of the floxed allele 13
weeks after transfer. At 10 weeks after the final pIpC
treatment, bone marrow was analyzed by flow cytome-
try, revealing that donor-derived Ly5.12CD342c-kit+
Sca-1+ HSCs were severely reduced in mutant chimeras
compared with control chimeras (Figure 5A). In contrast,
competitor-derived Ly5.1+CD342c-kit+Sca-1+ HSCs
in mutant chimeras were not impaired (Figure 5B).
These results suggest that the deficits in maintenance
of the HSC pool in the absence of CXCR4 are HSC
autonomous.
Analysis of the cell-cycling status of primitive hemato-
poietic cells revealed that competitor-derived wild-type
Ly5.1+c-kit+Sca-1+ cells in the bone marrow from mu-
tant chimeras demonstrated a smaller fraction in quies-
cent G0 cells and a larger fraction in actively dividing
(G1+S+G2/M) cells compared with c-kit
+Sca-1+ cells in
control chimeras (Figure 5C). This suggests that the
altered cell-cycle status in mutant chimeras is due to
an altered microenvironment.
CAR Cells Scattered throughout Bone Marrow
Are the Major Producers of CXCL12
The result that CXCL12-CXCR4 signaling is required to
maintain the HSC pool prompted us to examine further
the expression of CXCL12 in bone marrow. Our study
of mice with the GFP reporter gene knocked into the
CXCL12 locus (CXCL12-GFP knockin mice) showed
a population of reticular cells, which express CXCL12
at high amounts, with several long processes and
scattered throughout adult bone marrow (Tokoyoda
et al., 2004). Further, it has been shown previously that
CXCL12 is expressed in osteoblasts lining the bone
surface (Jung et al., 2006; Ponomaryov et al., 2000), in
bone (Katayama et al., 2006), and in endothelial cells
(Dar et al., 2005; Ponomaryov et al., 2000; Sipkins
et al., 2005). Histological analysis of CXCL12-GFP
knockin mice revealed that most cells expressing high
amounts of CXCL12 were not in close proximity to the
bone surface but were scattered throughout the intertra-becular space of the bone marrow cavity and GFP
expression was barely detectable in bone (Figure 6A).
Immunohistochemical analysis with antibodies against
the osteoblast marker osteocalcin revealed that the ma-
jority of osteoblastic cells that expressed osteocalcin
and were in close proximity to the bone surface ex-
hibited an undetectable expression of GFP (Figures
6B–6D; Figures S4A and S4B), but some of these cells
exhibited a much lower expression of GFP relative to
the reticular cells expressing high amounts of CXCL12
(Figures 6E–6G; Figures S4C and S4D). Thus, reticular
cells that expressed high amounts of CXCL12 were
termed CXCL12-abundant reticular (CAR) cells, and
our results indicate that CAR cells are the major
producer of CXCL12 in adult bone marrow. It has been
reported previously that the cells lining the bone sur-
face and expressing Jagged1 (Calvi et al., 2003) or
N-cadherin (Zhang et al., 2003) act as HSC niches.
Immunohistochemical analysis with antibodies against
Jagged1 or N-cadherin revealed that CAR cells ex-
hibited similar expression of Jagged1 and lower expres-
sion of N-cadherin relative to the cells lining the bone
surface (Figures 6H–6K; Figures S4E–S4H). Additionally,
Figure 5. Reduced HSC Pool and Increased Fraction of the Primitive
Hematopoietic Cells in Active Cell Cycle in Mice Reconstituted with
CXCR4f/null Bone Marrow Cells
Bone marrow cells (Ly5.2+Ly5.12) from MxCre-CXCR4f/null and
MxCre-CXCR4f/wt mice were transferred along with wild-type bone
marrow cells (Ly5.22Ly5.1+) into lethally irradiated Ly5.22Ly5.1+
recipients. Chimeric mice were treated with pIpC at 13 weeks after
transfer and their bone marrow was analyzed by flow cytometry at
10 weeks after the treatment (n = 3).
(A) Numbers of MxCre-CXCR4f/null and MxCre-CXCR4f/wt Ly5.12
CD342c-kit+Sca-1+ HSCs in bone marrow (p = 0.028).
(B) Numbers of competitor-derived Ly5.1+CD342c-kit+Sca-1+ HSCs
in bone marrow (p = 0.082).
(C) Analysis of cell-cycle status of c-kit+Sca-1+ cells after staining
with Ki67. The percentage of G0 cells (left) and G1+S+G2/M cells
(right) in competitor-derived wild-type c-kit+Sca-1+ cell population
in control and mutant chimeras (left, p = 0.005; right, p = 0.005).
Error bars represent SD of the mean.
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(A) A trabecular bone section from CXCL12-GFP knockin mice. Most cells expressing a high amount of GFP (green) are scattered throughout
intertrabecular space of the bone marrow cavity, and GFP expression is barely detectable in bone.
(B–G) Bone marrow sections from CXCL12-GFP knockin mice stained with antibodies against osteocalcin (red). Osteoblastic cells
lining the bone surface that exhibit undetectable expression of GFP (B–D) or a much lower expression of GFP relative to CAR cells (E–G) are
shown.
(H–K) Bone marrow sections from CXCL12-GFP knockin mice stained with antibodies against Jagged1 (red; [H] and [I]) or N-cadherin (red; [J] and
[K]). The nuclei of cells were labeled with TO-PRO3 dye (white; [I] and [K]). CAR cells (arrows; green), which exhibit similar expression of Jagged1
and lower expression of N-cadherin relative to the cells lining the bone surface (arrowheads; red), are shown.
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mice with antibodies against Sca-1 and the panendothe-
lial markers PECAM-1 and MECA-32 antigen revealed
that morphologicaly identifiable PECAM-1+ endothelial
cells in bone marrow expressed Sca-1 (data not shown;
Suzuki et al., 2006). In addition, Sca-1+ or MECA-32+ en-
dothelial cells exhibited a much lower to undetectable
expression of GFP relative to CAR cells (Figures 6L–
6N; Figures S4I–S4L). Interestingly, detailed observa-
tions revealed that Sca-1+ or MECA-32+ sinusoidal
endothelial cells were often surrounded by cell bodies
or the processes of some CAR cells (Figures 6L–6N; Fig-
ures S4I–S4L), as observed in fetal bone marrow (Ara
et al., 2003).
HSCs near Endosteum or the Sinusoidal
Endothelium Are in Contact with CAR Cells
Next we sought to elucidate interaction of HSCs with the
cells expressing CXCL12 in aged mice because the pro-
portion of HSCs in the c-kit+Sca-1+Lin2 cell population
increases with age (Morrison et al., 1996; Sudo et al.,
2000). Flow cytometric analysis revealed that approxi-
mately 40% of c-kit+Sca-1+Lin2 cells were CD342 in
bone marrow from 13-month-old mice (data not shown;
Sudo et al., 2000). Immunohistochemical analysis of
bone marrow sections from 13-month-old CXCL12-
GFP knockin mice with antibodies against c-kit and
Sca-1 revealed that almost all c-kit+Sca-1+ cells (45 of
48; 94%), which were Lin2 (Tokoyoda et al., 2004),
adjoined CAR cells, consistent with our previous study
(Figure S5 and data not shown; Tokoyoda et al., 2004).
In addition, CD150+CD482CD412 cells are enriched in
HSC activity and can be imaged (Kiel et al., 2005). Immu-
nohistochemical analysis of bone marrow sections from
13-month-old CXCL12-GFP knockin mice with anti-
bodies against CD150, CD48, and CD41 revealed that
0.0264% of cells in the sections were CD150+CD482
CD412 and almost all of CD150+CD482CD412 cells (34
of 35; 97%) were in contact with CAR cells (Figure S6
and data not shown). These results strongly suggest
that many HSCs are associated with CAR cells. Consis-
tent with previous studies (Kiel et al., 2005; Tokoyoda
et al., 2004), many c-kit+Sca-1+ and CD150+CD482
CD412 cells were found scattered throughout the mar-
row, and the remaining cells resided near the bone
surface (data not shown). Interestingly, almost all c-kit+
Sca-1+ and CD150+CD482CD412 cells near the endos-
teum (9 of 9; 100%) were also found in close association
with CAR cells (Figures 7A and 7B, and data not shown).
Many CD150+CD482CD412 cells are associated with
the sinusoidal endothelium in the bone marrow (Kiel
et al., 2005). Thus, we examined the interaction among
c-kit+Sca-1+ or CD150+CD482CD412 cells, CAR cells,
and bone marrow sinusoidal endothelial cells. Immuno-
histochemical analysis of CXCL12-GFP knockin mice
with antibodies against c-kit and Sca-1 revealed that
almost all c-kit+Sca-1+ (17 of 20; 85%) and CD150+
CD482CD412 cells (20 of 21; 95%) near the sinusoidal
endothelium were in contact with CAR cells surroundingendothelial cells in extravascular spaces (Figures 7C–
7H). Additionally, some c-kit+Sca-1+ (15 of 48; 31%)
and CD150+CD482CD412 (14 of 35; 40%) cells were in
contact with CAR cells that were not associated with
sinusoidal endothelial cells (data not shown). Together,
these results suggest that CAR cells might be a critical
component of HSC niches, including vascular niches.
Contact of the Primitive Hematopoietic Progenitors
with CAR Cells Is Maintained in the Absence
of CXCR4
We next examined the interaction of c-kit+Sca-1+ cells
with CAR cells in bone marrow from CXCR4 condition-
ally deficient mice. We crossed MxCre-CXCR4f/null
mice with CXCL12-GFP knockin mice. Mice were then
treated with pIpC to induce excision of the floxed allele
and were analyzed 10 weeks after the final pIpC treat-
ment. Flow cytometric analysis revealed that CD342
c-kit+Sca-1+Lin2 HSCs were severely decreased in
CXCL12-GFP-MxCre-CXCR4f/null mice compared with
control animals, suggesting that the majority of c-kit+
Sca-1+Lin2 cells are CD34+c-kit+Sca-1+Lin2 progenitors
in the mutants. Immunohistochemical analysis with anti-
bodies against c-kit and Sca-1 revealed that even in the
absence of CXCR4, almost all c-kit+Sca-1+ cells (76 of
84; 90%) adjoined CAR cells and the proportion of asso-
ciated c-kit+Sca-1+ cells was not reduced, suggesting
that CXCR4 is dispensable for the contact of CD34+
c-kit+Sca-1+Lin2 progenitors with CAR cells (Figures 7I
and 7J; Figure S7).
Discussion
We have shown previously that CXCL12-CXCR4 signal-
ing is involved in the colonization of bone marrow by
HSCs during ontogeny (Ara et al., 2003). Here we have
shown that, within adult bone marrow, CXCL12-
CXCR4 signaling plays a critical role in maintaining a
pool of HSCs in a cell-autonomous manner. It is possi-
ble that CXCL12 supports the survival and/or self-
renewing divisions of HSCs, because CXCL12 has previ-
ously been shown to enhance the engrafting capacity
of HSCs cultured in vitro with SCF and interleukin-6
(Broxmeyer et al., 2003). In addition, CXCL12 might act
as an inhibitor of the cycling status of HSCs to maintain
their pool. This possibility is consistent with the previous
results that in vivo administration of CXCL12 arrested
the cycling of primitive human hematopoietic progeni-
tors and enhanced the engrafting ability of SRCs in
NOD-SCID mice that were short-term reconstituted by
human fetal liver cells (Cashman et al., 2002). Alterna-
tively, CXCL12 might play a role in tethering HSCs in
their niches in which essential factors act on HSCs for
their maintenance. Although CXCL12 induced the
migration of c-kit+Sca-1+Lin2 cells and increased their
adhesion to vascular cell adhesion molecule (VCAM)-1
and fibronectin, expressed in CAR cells (data not
shown), the remaining c-kit+Sca-1+ cells stayed in con-
tact with CAR cells in CXCR4 conditionally deficient(L–N) Bone marrow sections from CXCL12-GFP knockin mice stained with antibodies against Sca-1 (red; [L] and [M]) and MECA-32 antigen (red,
[N]), expressed in sinusoidal endothelial cells. Endothelial cells (arrowheads; red), which exhibit a much lower to undetectable expression of GFP
relative to CAR cells and are often surrounded by CAR cells (arrows; green), are shown. S, vascular sinus.
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(A and B) Bone marrow sections from CXCL12-GFP knockin mice stained with antibodies against c-kit (blue) and Sca-1 (red). c-kit+Sca-1+ cells
(arrows; purple), which reside near the bone surface and are in close association with CAR cells, are shown.
(C–F) Bone marrow sections from CXCL12-GFP knockin mice stained with antibodies against c-kit (blue) and Sca-1 (red). c-kit+Sca-1+ cells
(arrows; purple), which contact CAR cells (green) surrounding morphological identifiable Sca-1+ endothelial cells (arrowheads; red), are shown
(D–F). Higher magnification of (D) is shown in (E). S, vascular sinus.
(G and H) A bone marrow section from CXCL12-GFP knockin mice stained with antibodies against CD150 (red), CD48 (blue), and CD41 (blue). A
CD150+CD482CD412 cell (arrow; red), which contacts the morphologically identifiable CAR cells (green) surrounding the vascular sinus is shown
(H). S, vascular sinus.
(I and J) A bone marrow section from CXCL12-GFP-MxCre-CXCR4f/null mice stained with antibodies against c-kit (blue) and Sca-1 (red).
c-kit+Sca-1+ cells (arrows; purple), which contact CAR cells (green) surrounding morphological identifiable Sca-1+ endothelial cells (arrowheads;
red) are shown (J). S, vascular sinus.
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signaling is dispensable for adhesive interaction of
HSCs as well as c-kit+Sca-1+ hematopoietic progenitors
with CAR cells; however, it has been difficult to assess
directly the impact of CXCR4 deficiency on HSC contact
with CAR cells because HSCs were severely reduced
in CXCR4 mutants. On the other hand, considering
that deficiencies in long-term repopulation by CXCR4-
deficient bone marrow cells might be partly due to the
homing defects of CXCR4-deficient HSCs and the fact
that CXCL12 is involved in homing of HSCs into bone
marrow through endothelial cells during ontogeny (Ara
et al., 2003), there is also the possibility that CXCL12
plays a critical role in homing of HSCs in the previously
reported constitutive physiological circulation of HSCs
in adult life (Schwarz and Bhandoola, 2004; Wright
et al., 2001). Further investigations will be needed to
clarify the mechanisms through which CXCL12 main-
tains the HSC pool.
Analysis of CXCL12-GFP knockin mice has shown that
CAR cells are the major producers of CXCL12 within
bone marrow. Thus, the results that almost all c-kit+
Sca-1+ and CD150+CD482CD412 cells, which contain
substantial numbers of HSCs, adjoined CAR cells sug-
gest that many HSCs are in contact with CAR cells and
receive CXCL12 signals mainly from these cells. On the
other hand, sinusoidal endothelial cells were often sur-
rounded by cell bodies or the processes of some CAR
cells and exhibited a much lower to undetectable expres-
sion of CXCL12 relative to CAR cells. This seems consis-
tentwith therecentfindingsof thestudiesof invivoconfocal
immunoimaging and immunohistochemistry that
CXCL12 is found in bone marrow vasculature (Dar
et al., 2005; Ponomaryov et al., 2000; Sipkins et al.,
2005) because CAR cells are closely associated with en-
dothelial cells. Considering that many HSCs are associ-
ated with sinusoidal endothelium (Kiel et al., 2005), our
findings that almost all c-kit+Sca-1+ and CD150+CD482
CD412 cells near the sinusoidal endothelium were in
contact with CAR cells surrounding endothelial cells in
the extravascular space suggest that HSCs in vascular
niches are in contact with CAR cells, raising the possibil-
ity that CAR cells are a critical cellular component of
vascular niches (Ara et al., 2003; Avecilla et al., 2004).
It has been reported previously that HSCs are in con-
tact with osteoblasts in the endosteum of bone marrow
(Arai et al., 2004; Calvi et al., 2003; Wilson and Trumpp,
2006; Zhang et al., 2003). CXCL12 is expressed in oste-
oblasts lining the bone surface (Jung et al., 2006; Pono-
maryov et al., 2000) and is likely deposited in the bone
matrix, although there is no evidence that osteocytes
express CXCL12 (Katayama et al., 2006). Our study
with CXCL12-GFP knockin mice revealed that a small
population of osteoblastic cells lining the bone surface
expressed CXCL12, albeit at a substantially lower
amount than CAR cells. Thus, we cannot rule out the
possibility that CXCL12 produced by osteoblasts lining
the bone surface acts on HSCs. However, because
most c-kit+Sca-1+ and CD150+CD482CD412 cells resid-
ing near the bone surface were also in contact with CAR
cells, we speculated that CAR cells might play a role in
the regulation of HSCs in osteoblastic as well as vascu-
lar niches in bone marrow. Ang-1, a ligand for the recep-
tor tyrosine kinase Tie2, is expressed exclusively inosteoblasts lining the bone surface based on immuno-
histochemical analysis and on the fact that overexpres-
sion of kinase dead (KD)-Tie2 as a dominant-negative
form of Tie2 affects the quiescent state of HSCs, sug-
gesting that Ang-1-Tie2 signaling is involved in main-
taining HSCs in a quiescent state in the endosteum
(Arai et al., 2004). Thus, HSCs are possibly supported
by different combinations of environmental factors in
osteoblastic and vascular niches. Ang-1 was also re-
ported to be produced by HSCs (Takakura et al.,
2000). It is important to know how Ang-1 and CXCL12
influence HSC fate in these niches.
What is the lineage nature of CAR cells? Depleting
osteogenic lineage cells with a 2.3 kb fragment from
the rat Col1a1 gene promoter (pOBCol2.3) driving thymi-
dine kinase (Col2.3DTK) induced a marked defect on
bone marrow hematopoiesis (Visnjic et al., 2004).
Although bone marrow reticular cells have been thought
to be fibroblastic in nature and the expression of the
osteoblast marker osteocalcin was below detection in
CAR cells in immunohistochemical analysis, CAR cells
are possibly progenitors of the osteogenic lineage con-
sidering that osteogenic lineage cells with long pro-
cesses were previously reported to be present in the
intertrabecular space of bone marrow (Rouleau et al.,
1990). Further studies on the phenotypic characteriza-
tion of CAR cells in wild-type and Col2.3DTK animals
would help to address this issue.
In CXCR4 conditionally deficient mice, G0 exit and G1
entry was substantially promoted in the primitive hema-
topoietic progenitors compared with wild-type mice
in which most primitive hematopoietic progenitors are
quiescent in the G0 phase. It is likely that lack of
CXCR4 results in HSC pool reduction, leading to an ex-
pansion of the more differentiated progenitors and com-
pensating for HSC defects. Experiments with chimeric
mice have suggested that these defects are due to an
altered microenvironment. In this case, the expression
of cytokines that enhance the entry of primitive hemato-
poietic progenitors into the active cell cycle might be
upregulated in the microenvironment of the mutants.
This study revealed the environmental factor essential
for maintaining the HSC pool and produced by bone
marrow stromal cell niches, including vascular niches,
where many HSCs might reside. It is known that
CXCL12 also acts on other organ-specific stem cells in-
cluding primordial germ cells (Raz, 2003). Our findings
provide a basis for probing the molecular mechanisms
that control maintenance of the stem cell pool within
microenvironmental niches in mammals.
Experimental Procedures
Mice
CXCL12-GFP knockin mice and CXCR4f/null mice (Ara et al., 2003;
Tokoyoda et al., 2004) were backcrossed more than seven times
with C57BL/6-Ly5.2+Ly5.12 mice. CXCR4f/null mice were crossed
with MxCre mice (Kuhn et al., 1995) to get MxCre-CXCR4f/null
mice. Cre expression was induced by intraperitoneally injection of
pIpC (300 mg per body for 4 times at 2 day interval; Sigma). Mice
were then injected with the same amount of pIpC for four more times
at 1 week intervals (eight injections in total). Deletion of the floxed
CXCR4 gene in the target cells was detected by flow cytometer or
qRT-PCR, and mice younger than 13 months of age were analyzed.
All animal experimentation was conducted in accordance with insti-
tutional guidelines.
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The bone marrow cell suspensions were flushed from femurs and tib-
ias. Monoclonal antibodies against c-kit (2B8), Sca-1 (E13-161.7),
CD34 (RAM34), CD3e (145-2C11), CD4 (GK1.5), CD8a (53-6.7),
CD11b (M1/70), Gr-1 (RB6-8C5), B220 (RA3-6B2), Ter119, CXCR4
(2B11), and Ly5.2 (104); and rat IgG isotype controls were obtained
from BD Biosciences. Biotinylated antibodies were visualized with
streptavidin-PerCP or streptavidin-PerCPCy5.5 (BD Biosciences).
CD342c-kit+Sca-1+Lin2 cells were stained as previously described
(Osawa et al., 1996). Hoechst 33342 (Sigma) staining for SP cells
was performed as described (Goodell et al., 1996). Stained cells
were analyzed with FACSCalibur or sorted with FACSVantageSE
(BD Biosciences).
Cell-Cycle Analysis
To analyze the cell-cycle status by PY staining, cells were first
stained with APC-conjugated c-kit antibody, PE-conjugated Sca-1
antibody, and biotinylated lineage antibodies against CD3e, CD4,
CD8a, B220, Gr-1, Mac-1, and Ter119. Biotinylated antibodies
were visualized with streptavidin-PerCPCy5.5 and then fixed with
4% PFA. Fixed cells were stained with 10 mg/ml Hoechst33342
and 0.5 mg/ml PY (Sigma) as previously described (Ladd et al.,
1997). Cells were analyzed with FACSAria (BD Biosciences). To
analyze the cell-cycle status by Ki67, cells were stained with
APC-conjugated c-kit antibody, PE-conjugated Sca-1 antibody,
biotinylated CD34 antibody, FITC-conjugated Ki-67 antibody (B56;
BD Biosciences), and 7AAD. Biotinylated antibodies were visualized
with streptavidin-Pacific Blue (Invitrogen). Intranucleus staining was
performed with BrdU flow kit (BD Biosciences) according to the
manufacturer’s instructions without DNase treatment. In the case
of some competitive repopulation mice, cells were stained with
PECy5-conjugated Ly5.1 antibody (A20; eBioscience) as well as
antibodies against c-kit, Sca-1, and Ki67. Cells were analyzed with
FACSCalibur or FACSAria.
Long-Term Culture-Initiating Cell Assay
The long-term culture-initiating cell (LTC-IC) assay was performed as
described previously (Stier et al., 2005). To prepare stromal layers,
murine bone marrow nucleated cells were cultured in 96-well flat-
bottomed plates in long-term culture medium (M5300; StemCell
Technologies). Irradiated stromal layers were seeded with serially
diluted bone marrow single-cell suspensions in the same medium.
Marrow was seeded at 2-fold dilutions (1,560–200,000 cells per
well) for nucleated bone marrow cells. To measure LTC-ICs, the
semisolid cytokine-containing methylcellulose medium for CFC
(Methocult M3434; StemCell Technologies) was overlaid into the
wells at 6 weeks and the colonies were counted at day 12. A limiting
dilution analysis software program (L-Calc; StemCell Technologies)
was used to calculate the frequency of LTC-ICs in the cell population.
Competitive Repopulation Units Assay
Limiting dilutions of bone marrow cells to be tested were mixed with
2 3 105 bone marrow cells from 8-week-old C57BL/6-Ly5.22Ly5.1+
mice and transplanted into lethally irradiated (10Gy) C57BL/6-
Ly5.22Ly5.1+ mice. CRU amounts were determined in two separate
experiments, by injecting 4 to 8 recipients at each cell dose in
a dilution series. Cell doses ranged from 7.43 103 to 6.03 105 cells.
Peripheral blood cells of the recipient mice were taken 4 months
after transplantation, and lineage cells were analyzed by flow cytom-
eter. CRU frequencies in the test bone marrow samples were calcu-
lated by applying Poisson statistics to the proportion of negative re-
cipients at different dilutions via L-Calc.
Adoptive Transfer
Unfractionated 2 3 106 bone marrow cells to be tested were mixed
with 1 3 106 bone marrow cells of C57BL/6-Ly5.22Ly5.1+ mice as
competitor cells and were transplanted into lethally irradiated
(10Gy) C57BL/6-Ly5.22Ly5.1+ mice. At 13 weeks after transplanta-
tion, recipients were treated with pIpC, resulting in excision of the
conditionally targeted alleles. Mice were analyzed at 10 weeks after
the final pIpC injection.5-FU Exposure In Vivo
The mice were used at 16 to 32 weeks after the final pIpC injection.
After we determined the sublethal dose of weekly administration of
5-FU (Kyowa Hakko), pIpC-treated MxCre-CXCR4f/wt or MxCre-
CXCR4f/null mice were administered 5-FU intraperitoneally weekly
at a dose of 120 mg/kg four times. The survival rates of the groups
were defined.
Immunohistochemical Analysis
Immunostaining was performed as described in our previous
publication (Tokoyoda et al., 2004). In brief, bone samples were fixed
in 4% paraformaldehyde and equilibrated in 30% sucrose/phos-
phate buffered saline (PBS). Fixed samples were embedded in
OCT medium (Sakura) and frozen in cooled hexane. Sections of
undecalcified femoral bone were generated via Kawamoto’s film
method (Cryofilm transfer kit; FINETEC). The 7 mm thick cryostat
sections were first blocked with 5% fetal calf serum (FCS)/PBS
and then stained with monoclonal antibodies in blocking buffer.
The sections were mounted with PERMAFLUOR (Beckman Coulter),
and confocal microscopy was performed with a LSM 510 META (Carl
Zeiss). The following antibodies were used for immunostaining:
purified monoclonal antibodies against CD150 (TC15-12F12.2) (Biol-
egend), Sca-1 (E13-161.8), CD41 (MWReg30), and CD48 (HM48-1);
biotinylated monoclonal antibodies against c-kit (2B8), PECAM-1
(MEC13.3), panendothelial cell antigen (MECA-32) (BD Biosciences);
and purified rabbit polyclonal antibody against Osteocalcin (M173)
(Takara Bio), Jagged1 (H-114) (Santa Cruz Biotechnology), and
N-Cadherin (YS) (IBL). Antibodies against Sca-1 and CD150 were
conjugated with Alexa Fluor 555 by antibody-labeling kit (Invitro-
gen). For secondary antibodies, Cy5-conjugated goat anti-rat IgG
antibody and Cy5-conjugated goat anti-Armenian Hamster IgG anti-
body (Jackson ImmunoResearch Laboratories) were used. Biotiny-
lated antibodies were visualized with streptavidin-Alexa Fluor 546
or streptavidin-Alexa Fluor 647 (Invitrogen). Immunostaining with
rabbit polyclonal antibody was performed with Zenon rabbit IgG
labeling kit (Invitrogen) according to the manufacturer’s instruc-
tions. The nuclei of cells were labeled with TO-PRO3 or SYTO62
dye (Invitrogen).
QRT-PCR Analysis
QRT-PCR was performed as described in our previous publication
(Tokoyoda et al., 2004). The primers used for the PCR reaction
were as follows: Junb: 5-CACCCGGCACAGCTGG-3, 5-TACGGTCT
GCGGTTCCTCTTTAA-3, Vegfa: 5-CAGAGCGGAGAAAGCATTTGT-3,
5-CGCGAGTCTGTGTTTTTGCA-3, Tek: 5-TTGCTCTGGGAGATTGT
TAGCTT-3, 5-GCTCCGCGCACGTCA-3. Values for each gene were
normalized to the relative quantity of Gapdh mRNA in each sample.
Statistical Analysis
The significance of the difference between groups in the experi-
ments was evaluated by analysis of variance followed by a one-
tailed Student’s t test.
Supplemental Data
Eight Supplemental Figures can be found with this article online at
http://www.immunity.com/cgi/content/full/25/6/977/DC1/.
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